Application for Tysabri as first line treatment

Biogen and Elan, the manufacturers of natalizumab (Tysabri), have applied to the EMA (for Europe) and FDA (for America) to expand the licence for the drug to include people with relapsing remitting MS who do not have antibodies to the JC virus. Biogen press release Natalizumab (Tysabri) - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news